Engineered FGF19^ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model.

ABSTRACT:

Background

The major safety concern of the clinical application of wild type FGF19 (FGF19^WT) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19^ΔKLB, which have same effects on glycemic control and bile acid production but much less mitogenic activity. However, it remains unclear as to whether FGF19^ΔKLB ameliorates intrahepatic cholestasis.

Results

We found that, similar to that of FGF19^WT, the chronic administration of FGF19^ΔKLB protects mice from cholestatic liver injury in these two models. The therapeutic benefits of FGF19^ΔKLB on cholestatic liver damage are attributable, according to the following mechanistic investiga

SUBMITTER: Shi L 

PROVIDER: S-EPMC10548598 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature